Clin2
NCT07770737Possibly a fitNot yet recruiting

Heart protection with diabetes medicines

Type 2 Diabetes Mellitus (T2DM)Cardiovascular DiseasesStage B Heart Failure

Part of Heart & circulation, Hormones & metabolism clinical trials.

This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
19 years and older
Study type
Observational

Who can take part

  • You are 19 years or older (for the first part of the study) or 50 years or older (for the second part).
  • You have been diagnosed with type 2 diabetes.
  • You are starting a new diabetes medicine, such as an SGLT2 inhibitor or a GLP-1 receptor agonist.
  • You have not taken a similar medicine in the 90 days before starting the new one.
  • You are not pregnant, and you do not have type 1 diabetes or other specific types of diabetes.
  • For the second part, you must not have any signs or symptoms of heart failure, and you must have certain risk factors like high blood pressure or long-standing diabetes.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06642623Recruiting· Phase 4
Study on heart and kidney health in type 2 diabetes

This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.

Seoul
NCT04286399Recruiting· Phase 4
Prevention trial for heart outcomes in people with type 2 diabetes

This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.

Singapore
NCT07614230Recruiting· Phase 4
SGLT2 drugs and heart artery health in diabetes

This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.

Beijing, Beijing Municipality
NCT06203860Recruiting
Heart-focused clinic for diabetes and heart disease

This study is testing whether a special heart-focused clinic can help people with type 2 diabetes who also have heart or blood vessel problems. If you have both diabetes and a heart condition like prior heart attack, stroke, heart failure, or hard-to-control high blood pressure, this program may support your health.

Svendborg, Region Syddanmark
NCT06959784Enrolling by invitation· Phase 4
A study on new diabetes drugs for heart health and remission

This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.

Beijing
NCT06627322Recruiting
Diabetes type 2 trial for people with heart risks

This study compares different diabetes medicines to see which works best for people with type 2 diabetes who also have heart or blood vessel risks. It aims to find better treatment to protect your heart and kidneys.

Daegu

Hear when a new Cardiovascular Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.